Key terms
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NBIX news
Yesterday
9:36am ET
Tesla, Airbnb upgraded: Wall Street’s top analyst calls
Yesterday
7:56am ET
Jefferies Sticks to Its Buy Rating for Neurocrine (NBIX)
Yesterday
7:50am ET
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Day One Biopharmaceuticals (DAWN) and Roche Holding AG (OtherRHHVF)
Yesterday
7:30am ET
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), HealthStream (HSTM) and Vertex Pharmaceuticals (VRTX)
Yesterday
6:40am ET
Wall Street Analysts Are Neutral on Top Healthcare Picks
Yesterday
6:21am ET
Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Day One Biopharmaceuticals (DAWN)
Yesterday
5:42am ET
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Biogen (BIIB) and Neurocrine (NBIX)
Apr 23
4:41pm ET
Wells Fargo upgrades Neurocrine with pipeline ‘turning a corner’
Apr 23
4:09pm ET
Neurocrine upgraded to Overweight from Equal Weight at Wells Fargo
Apr 23
2:20pm ET
Analysts Are Bullish on These Healthcare Stocks: Neurocrine (NBIX), Carisma Therapeutics (CARM)
Apr 23
10:29am ET
Neurocrine NBI-1065845 results ‘look potentially promising,’ says RBC Capital
Apr 23
9:41am ET
Analysts Offer Insights on Healthcare Companies: Danaher (DHR), Neurocrine (NBIX) and Medtronic (MDT)
Apr 23
8:40am ET
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Ultragenyx Pharmaceutical (RARE)
Apr 23
7:08am ET
Neurocrine’s NBI-1065845 shows efficacy in major depressive disorder
Apr 16
4:11pm ET
Neurocrine, Sentia Medical Sciences extend CRF research collaboration
Apr 16
8:00am ET
Analysts’ Top Healthcare Picks: Neurocrine (NBIX), Ultragenyx Pharmaceutical (RARE)
Apr 16
7:06am ET
Voyager announces selection of development candidate for GBA1 Program
Apr 09
12:30am ET
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Shandong Weigao Group Medical Polymer Co (OtherSHWGF) and Cormedix (CRMD)
Apr 08
4:31am ET
Analysts Offer Insights on Healthcare Companies: Icon (ICLR) and Neurocrine (NBIX)
Apr 03
5:16am ET
Wells Fargo Reaffirms Their Hold Rating on Neurocrine (NBIX)
Mar 28
8:31am ET
Neurocrine initiates Phase 1 study of NBI-1065890
Mar 20
7:03am ET
Neurocrine price target raised to $158 from $148 at JPMorgan
Mar 14
7:15am ET
Maintaining Hold Rating for Neurocrine Biosciences Amid Reduced Competition and Long-Term Market Potential
Mar 14
7:15am ET
Strong Buy on Neurocrine Biosciences as Crinecerfont Leads in CAH Market, Backed by Solid Pipeline and Underappreciated Value
Mar 14
6:20am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX), Jazz Pharmaceuticals (JAZZ) and scPharmaceuticals (SCPH)
Mar 13
7:23am ET
Neurocrine price target raised to $200 from $170 at Oppenheimer
Mar 01
8:40am ET
Analysts Are Bullish on These Healthcare Stocks: Tenet Healthcare (THC), Moderna (MRNA)
Feb 26
7:16am ET
Voyager Therapeutics reports selection of gene therapy development candidate
Feb 23
11:55am ET
JPMorgan biotech analysts to hold an analyst/industry conference call
Feb 23
11:00am ET
JPMorgan biotech analysts to hold an analyst/industry conference call
Feb 22
7:32am ET
RBC Capital Keeps Their Hold Rating on Neurocrine (NBIX)
No recent press releases are available for NBIX
NBIX Financials
Key terms
Ad Feedback
NBIX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NBIX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
